Oncology Times - OncTimes Talk
Activity Overview
Episode publication activity over the past year
Episodes
Episode 3, Better Informed Patient Journeys
Contributed by Lukas
In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking wit...
From Ironman to Advocate: Tom Hulsey’s Journey Through Prostate Cancer and Purpose
Contributed by Lukas
In this episode of OncTimes Talk, we chat with Tom Hulsey—athlete, author, and prostate cancer survivor—about the life-altering moment he received...
Accurate and Actionable: How Oncologists Get Fast, Comprehensive Therapeutic Insights from the OncoExTra® Test
Contributed by Lukas
In this third episode of the OncoExTra® podcast series, host Ruchika Talwar, MD, talks with Christy Russell, MD, Vice President of Medical Affairs at...
Empowering Cancer Care Through Movement: A Conversation with Sami Mansfield
Contributed by Lukas
In this episode of OncTimes Talk, we chat with Sami Mansfield, ACSM-CET, PN1, the founder of Cancer Wellness for Life, an organization dedicated to de...
Defying the Odds: Katie Coleman's Journey from Diagnosis to Advocacy
Contributed by Lukas
In this episode of OncTimes Talk, we chat with Katie Coleman. Diagnosed with an ultra-rare stage IV kidney cancer in 2020, her prognosis had a chance ...
Making Comprehensive Genomic Profiling More Accurate for Everyone: The Importance of Patient-Matched Tumor-Normal Sequencing
Contributed by Lukas
In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innova...
Transforming colorectal cancer management with tumor informed ctDNA testing
Contributed by Lukas
In this episode, Dr. Ruchika Talwar, a urologic oncologist at Vanderbilt University Medical Center, Dr. Adham Jurdi, a medical oncologist and Senior D...
Lessons in Resilience: Dr. Susan MacDonald's Healthcare Journey
Contributed by Lukas
In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urology at Penn ...
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk
Contributed by Lukas
Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a s...
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer
Contributed by Lukas
At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therap...
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities
Contributed by Lukas
Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group...
Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance
Contributed by Lukas
A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examina...
Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease
Contributed by Lukas
At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial ...
Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer
Contributed by Lukas
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking wit...
Episode 2, HRD Testing Deep-Dive
Contributed by Lukas
In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking wi...
KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma
Contributed by Lukas
The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEY...
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified
Contributed by Lukas
Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs th...
Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma
Contributed by Lukas
Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to i...
Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development
Contributed by Lukas
A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to devel...
Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer
Contributed by Lukas
A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 st...
Are You Giving Patients What They Want?
Contributed by Lukas
Steven Wood, PhD, Healthgrades VP, explains the health care ratings company’s survey findings that reveal what cancer patients said were the top thr...
ESMO Reports Neoadjuvant Therapy for TNBC, Combination Checkpoint Inhibition, Artificial Intelligence & More
Contributed by Lukas
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 C...
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified
Contributed by Lukas
The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEY...
The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front
Contributed by Lukas
In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinic...
Digital Twin Brings AI Power to Individualize Cancer Management
Contributed by Lukas
The prospect of markedly raising chemotherapy response rates and extending patient survival has been held out by scientists reporting a new AI-powered...
Wnt Signaling Pathway Inhibitor Suggests Toxicity-Free Cure Potential for Hepatoblastoma
Contributed by Lukas
The prospect of a minimally toxic, chemotherapy-free cure for hepatoblastoma is held out by findings from a mouse model using the small-molecule drug ...
Anti-HER2 Combination Found Effective in HER2-Altered Bile Duct Cancers
Contributed by Lukas
A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful responses to pat...
FGFR-3 Inhibitor Has Early Clinical Activity in Advanced Urothelial Cancer
Contributed by Lukas
The fibroblast growth factor receptor-3 (FGFR-3) inhibitor TYRA-300 has been found safe with dose-dependent responses and disease control in the Phase...
Antibody-Drug Conjugate “Promising Efficacy” in HER2-Positive and HER2-Low Breast Cancer
Contributed by Lukas
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy ...
Radiation Delivery by Mini Protein Brings Promise for Metastatic Urothelial & Other Solid Tumors
Contributed by Lukas
The mini-protein radiopharmaceutical AKY-1189, designed to deliver the alpha-emitting isotope Actinium-225 (225Ac) to tumors expressing the Nectin-4 t...
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors
Contributed by Lukas
Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis f...
Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer
Contributed by Lukas
Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overall su...
Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma
Contributed by Lukas
The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chem...
Findings at ESMO 2024 Highlighting the Benefit of Neoadjuvant Therapies
Contributed by Lukas
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 C...
Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy
Contributed by Lukas
When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “...
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy
Contributed by Lukas
A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of ...
Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma
Contributed by Lukas
Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CV...
Circulating Tumor DNA Directs Precision Management for Ovarian Cancer
Contributed by Lukas
Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precisi...
Cardio-Oncology: Many Cancer Treatment Cardiotoxicities Still to Be Understood
Contributed by Lukas
The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, according to ...
A Clinical Research Consortium for MDS
Contributed by Lukas
Mikkael A. Sekeres, MD, MS—who’s co-chairing the unique initiative to bolster research for the rare disease—explains what’s on the agenda and ...
Emerging Potential for Cell Therapies in Ovarian Cancer and Other Solid Tumors
Contributed by Lukas
Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Society of Clin...
Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment
Contributed by Lukas
An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chin...
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer
Contributed by Lukas
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual...
World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology’s Globally Upscale 2024 Annual Meeting
Contributed by Lukas
At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology ...
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer
Contributed by Lukas
A large international cohort study has found that women testing positive for the BRCA mutation who chose to breastfeed their babies after treatment fo...
Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients
Contributed by Lukas
Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to da...
HPV Vaccination Prevents HIV-Related Cancers in Men
Contributed by Lukas
HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already...
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia
Contributed by Lukas
A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidat...
What I Love About Hematology/Oncology: Pamela Crilley, DO
Contributed by Lukas
Find out what intrigued HemOnc Times Editorial Advisory Board Member Pamela Crilley, DO, Cancer Treatment Center of America, Philadelphia, about worki...
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers
Contributed by Lukas
Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observational stud...
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought
Contributed by Lukas
Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (...
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes
Contributed by Lukas
The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymph...
Are You Providing Adequate Palliative Care?
Contributed by Lukas
David E. Weissman, MD, founded the Palliative Care Center at the Medical College of Wisconsin, serves as Director of the Medical School Palliative Car...
MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival
Contributed by Lukas
When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-t...
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic
Contributed by Lukas
An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASC...
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma
Contributed by Lukas
A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically s...
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer
Contributed by Lukas
Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effective as ...
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia
Contributed by Lukas
Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibit...
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma
Contributed by Lukas
Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced es...
CMS Innovation
Contributed by Lukas
Alen Voskanian, MD—Innovation Advisor to the Centers for Medicare and Medicaid Services—describes the CMS project to test new payment and service ...
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy
Contributed by Lukas
Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+),...
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer
Contributed by Lukas
When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung...
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
Contributed by Lukas
New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibit...
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes
Contributed by Lukas
A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has be...
INTERLACE Study Boosts Cervical Cancer Survival
Contributed by Lukas
A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standar...
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma
Contributed by Lukas
The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as ad...
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC
Contributed by Lukas
A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung can...
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers
Contributed by Lukas
Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 stat...
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic
Contributed by Lukas
An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with ...
Exercise Deters Prostate Cancer Death & Progression
Contributed by Lukas
Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Da...
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
Contributed by Lukas
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or ...
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
Contributed by Lukas
An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer...
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers
Contributed by Lukas
Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a person...
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery
Contributed by Lukas
Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral...
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed
Contributed by Lukas
The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 yea...
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain
Contributed by Lukas
A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving ther...
Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection
Contributed by Lukas
Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the...
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema
Contributed by Lukas
Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (a...
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes
Contributed by Lukas
New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-...
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer
Contributed by Lukas
Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil...
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer
Contributed by Lukas
Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers.  ...
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations
Contributed by Lukas
The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the...
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab
Contributed by Lukas
About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherap...
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia
Contributed by Lukas
An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—bo...
Important Mantle Cell Lymphoma Findings From the Sympatico Study
Contributed by Lukas
How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympati...
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress
Contributed by Lukas
2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation o...
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
Contributed by Lukas
The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard o...
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
Contributed by Lukas
A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or wer...
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
Contributed by Lukas
Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercati...
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
Contributed by Lukas
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they ...
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones
Contributed by Lukas
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and re...
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease
Contributed by Lukas
The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete re...
Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients
Contributed by Lukas
A real-world study reported at the ESMO Breast Cancer 2023 Annual Congress identified a risk for inappropriate therapeutic decision-making resulting f...
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma
Contributed by Lukas
With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a P...
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
Contributed by Lukas
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosin...
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD
Contributed by Lukas
In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibi...
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD
Contributed by Lukas
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditi...
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active
Contributed by Lukas
Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inh...
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
Contributed by Lukas
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they ...
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones
Contributed by Lukas
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and re...